O B SH: The equal distribution of 2 billion vaccines begins in 2021

About 2 billion doses of vaccines against COVIED-19 has been provided for proportional distribution in 2021 to 190 countries that have signed the partnership agreement at the World Health Organisation's table, according to an organisation's announcement Friday.

Officials of the vaccine's production companies said they expect to begin sending vaccines in the first quarter of 2021. The partnership known as COVAX initials said that this amounts to 1.3 billion doses for low- and medium-income countries. Already that the first remittances of the vaccine have reached some of the higher income countries, and another was added to the U.S. vaccine efforts, the rest of the world remains waiting for a solution to provide vaccines.

COVAX was created to avoid the usual delays in access to treatment and health equipment that are often observed in low income countries compared to rich countries. “Our goal for equality in distributing vaccines against COVID-19 is sound and sound,” said Seth Berkeley, chief executive of the Alliance for Vaccina group that will lead the operation to distribute vaccines on behalf of COVAX.

Mr. Berkeley said he expects the first amount of vaccines to be used for health workers and most endangered individuals and will be sent by the end of June. After that, the amount of vaccines available and distribution will be added through this operation, with the aim of vaccinating 20% of the population of COVAX within 2021.

Just hypothetical.
For the time being, none of the vaccines in this group's portfolio have yet to get approval from regulatory entities, and there are still many questions about the funds for their purchase and distribution. It's hard to say that this amount of 2 billion doses of vaccine is more than just hypothese at the moment, said Kate Elder, an advisor to vaccines near the non-profit organisation without Borders.

According to the report, COVAX has signed a memorandum of understanding with the American pharmaceutical company Johnson & Johnson for 500 million vaccines, which are still in clinical trials. The company says it expects to get results in January. COVAX has also signed a preliminary agreement with the British company AstraZeneca for 170 million doses of its candidate vaccine. This figure is much smaller than the 300 million doses mentioned in the June memorandum of understanding, said Mrs. Elder.

Currently the COVAX partnership has no access to the first two vaccines, the Pfizer Company's/ B NTech and Modernna Company vaccine. COVAX is in talks with these companies, but has not yet reached agreement, said Richard Hatchett, chief executive of the Coalition for Innovation in response to the Epidemis, who is leading research-developing for COVAX.

This organisation has provided $2.4 billion to start purchasing vaccines for the interest of low and medium-income countries. The organisation says it needs $4.6 billion to complete the process and another 1.4 billion to pay for distribution. We need extra doses. We need more funds. But we have a clear way ahead to secure the first 2 billion doses,” said Mr. Berkeley.